The Division of Hematology/Oncology/BMT provides care by a team of experts knowledgeable in the specialized medical evaluation and treatment of children with cancer and blood disorders in the Province of British Columbia and Yukon. This team also provides consultative and directive care for patients requiring hematopoietic stem cell transplantation for both malignant and non-malignant conditions.
The Division is very proud of the passion, leadership and personal commitment demonstrated by all its members in the care and management of our patients.
American Society of Bone Marrow Transplantation (ASBMT)
American Society of Clinical Oncology (ASCO)
American Society of Pediatric Hematology Oncology (ASPHO)
Association of Hemophilia Clinic Directors of Canada (AHCDC)
Canadian Association Child Neurology Committee
Canadian Blood and Marrow Transplant Group
Canadian Children’s Thrombophilia Society
Canadian Congress of Neurological Sciences
Canadian Pediatric Brain Tumor Consortium
Canadian Pharmacogenomic Network for Drug Safety (CPNDS)
Children’s & Women’s Hospital Research Ethics Board (REB)
Children’s Cancer Group‐Brain Tumour Strategy Group, Neurosciences Scientific Committee
Children’s Oncology Group (COG)
Children’s Wish Foundation
CIBMTR Pediatric Cancers Working Committee
CIBMTR Metabolic Diseases and Immune Deficiencies Working Committee
Graduate Student Supervisor Committee
International Histiocyte Society
International Society on Thrombosis and Haemostasis (ISTH)
Musculoskeletal & Sarcoma Tumour Group
Pediatric Blood and Marrow Transplant Consortium (PBMTC)
Pediatric Hematology Oncology Clinic Improvement Committee (CLIC)
Provincial Home Hemosiderosis Program
Societe Internationale d’Oncologie Pediatrique – SIOP
Society of Neuro‐oncology
Thalassemia International Federation
Balding for Dollars
UPDATED AUG 10 2018
The Division has a robust basic science and translational research program with 7 PhD researchers. It is a strong clinical research unit with the Division being a full member of the Children’s Oncology Group (COG), a worldwide cooperative research group, and is one of 4 Canadian Institutions offering Developmental Therapeutics to children with relapsed malignancies, providing access to Phase 1 and 2 trials and access to novel agents.
Clinical research interests include clinical trials, cancer molecular biology, immunological aspects of transplantation, peripheral blood stem cell infusion post-intensive chemotherapy, immune- and cellular therapy. Other interests include participation in the Canadian Childhood Thrombophilia Program, and hematology clinical trials. A wide variety of research projects are available to fellows.
The Division of Hematology/Oncology/BMT has one of the most sought after subspecialty residency programs in Canada and attracts clinical fellows from around the world. A three year Royal College accredited training program in clinical hematology/oncology/bone marrow transplantation is offered.
All levels of trainees in the Division are exposed to lectures, mentorship, physician development, journal clubs and research opportunities. The rotations include inpatient, hematopathology, adult bone marrow transplant and adult lymphoma/radiation therapy service, blood banking, ambulatory clinics, research and electives. Candidates are required to have completed a minimum of three core years in general pediatrics.
Currently, we have two faculty members (Dr. Sylvia Cheng and Dr. Melissa Harvey) pursuing higher qualifications in Medical Education.
The Division sees about 140 new oncology patients per year with an overall survival rate of 83% with these children having ongoing follow up. Additionally, more than 300 new hematology patients are seen each year, many of whom have ongoing follow up.. The Division also performs an average of 35 stem cell transplants per year. In the 2015/16 fiscal year there were 10,987 outpatient visits and 7,511 inpatient days. The Provincial Pediatric Oncology/Hematology Network is a Network that includes parent advocates and community health care providers, and operates under the guidance of BC Children’s Hospital and the BC Cancer Agency, supported by Child Health BC. The Network supports community hospitals and practitioners, and develops partnerships with other health care facilities to enable seamless and integrated care for patients on treatment and off treatment and their families. This includes telehealth and outreach clinics
The team works in close collaboration with the BC Cancer Agency and its community centres and clinics in providing treatment and follow-up for children with cancer. Adolescents over the age of 17 at diagnosis should be referred to the BC Cancer Agency. In special cases, older adolescents will be considered for treatment at BCCH.
The program is a member of the Children’s Oncology Group (COG), a worldwide cooperative research group and collaborates with numerous other National and International collaboratives. The program participates in both Phase1 and 2 trials offering innovative therapies. Children’s cancer specialists are in constant communication with centers all over the world and are able to decide the best possible treatment for any childhood cancer.
We provide consultative service and directive care for patients with complex hematological disorders such as bleeding disorders, red cell disorders, thrombosis, cytopenias, and bone marrow failure syndromes.
There are at least 3,000 survivors of childhood cancer in BC. Children receive comprehensive medical follow up at Children’s Hospital until they are age 18-22 or at least 5 years from completion of treatment. They have access to a vocational counsellor. BC Cancer Agency and BC Children’s Hospital have recently created the Adult Childhood Cancer Survivors Program for childhood cancer survivors. As part of this program, a new clinic called the Late Effects, Assessment and Follow-up (LEAF) Clinic is providing ongoing medical, nursing, and psycho-social support to adult survivors of childhood cancer. Many of these long term survivors are not aware of the serious late health risks that they face as a result of their previous treatment and efforts are being made to trace and contact long term survivors and ensure that they are receiving appropriate care.
Blood and Marrow Transplant Program (BMT)
The BMT Program has been in operation since 1980. The program performs approximately 35 BMTs annually. This includes autologous peripheral blood stem cell and marrow transplants, and allogeneic cord, peripheral blood stem cell, and marrow transplants.
Dr. Caron Strahlendorf (Division Head)
Dr. Sylvia Cheng
Dr. Jeffrey Davis (BMT Director)
Dr. David Dix
Dr. Jess Halparin
Dr. Melissa Harvey (Education Director)
Dr. John K Wu (Hematology Director)
Dr. Rebecca Deyell (0.8FTE)
Dr. Juliette Hukin (Neuro-Oncology Director) (0.7FTE)
Dr. Sheila Pritchard (Late Effects Director) (0.8 FTE)
Dr. Rod Rassekh (0.8FTE)
Dr. Paul Rogers (0.3FTE)
Dr. Jacob Rozmus (0.4FTE)
Dr. Kirk Schultz (Research Director) (0.35FTE)
Dr. Bjorn Baadjes
Dr. Leslie Cohen
Dr. Elaine Peddie
Dr. Svjetlana Ruzic
Dr. Lucy Turnham
Dr. Ann Van Eyssen
Dr. Judy Wolfe
Dr. Peggy Wong
Dr. Karen Goddard (Radiation Oncology)
Dr. Derek Prevost (SMH)
Dr. Hanna Reysner (SMH)
Dr. Ewa Lunaczek-Motyka (Victoria General)
Dr. Philipp Lange
Dr. James Lim
Dr. Chris Maxwell
Dr. Catherine Pallen
Dr. Gregor Reid
Dr. Poul Sorenson
Evelyne Lau, Assistant to Division Head